Abstracts tagged "Scleroderma"

Abstract Number: 0625 • ACR Convergence 2023
Use of Heated Gloves for Raynaud’s Phenomenon in Systemic Sclerosis
Kimti Kumar¹, Nor Hashimah Abu Mansor Matardiah², Kim Griggs³, Aline Kunnel⁴, Jennifer Walker⁵ and Susanna Proudman⁶, ¹SA Health and University of Adelaide, Millswood, Australia, ²Tuanku Fauziah Hospital, Kangar, Malaysia, ³Royal Adelaide Hospital, Adelaide, Australia, ⁴South Australian Health and Medical Research Institute, Adelaide, Australia, ⁵Flinders Medical Centre and Royal Adelaide Hospital, Bedford Park, Australia, ⁶Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia
Background/Purpose: RP and its ischaemic complications are a major cause of morbidity in SSc. Non-pharmacological measures to minimise cold exposure can play a vital role…
Abstract Number: 0788 • ACR Convergence 2023
Whole Exome Sequencing and Evolutionary Action Missense Mutation Analysis Identifies MICB as a New SSc Susceptibility Locus and the Interferon Pathway as Contributors to SSc Pathogenesis
Shamika Ketkar¹, Hongzheng Dai¹, Brian Dawson¹, Lindsay Burrage¹, David Murdock¹, Jennifer Asmussen¹, Kevin Wilhelm¹, Olivier Lichtarge¹, Martin Kerick², Javier Martin³, Shervin Assassi⁴, Brendan Lee¹ and Maureen Mayes⁵, ¹Baylor College of Medicine, Houston, TX, ²Spanish National Research Council, Granada, Spain, ³Instituto de Parasitologia y Biomedicina Lopez-Neyra - CSIC, Granada, Spain, ⁴University of Texas McGovern Medical School at Houston, Houston, TX, ⁵Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX
Background/Purpose: Systemic Sclerosis (SSc) is characterized by fibrosis of the skin and internal organs associated with vasculopathy and autoantibodies and exhibiting wide clinical heterogeneity. Contributors…
Abstract Number: 1216 • ACR Convergence 2023
“I Call It Zombie Hands and Feet, That’s Actually How I Found out I Had This Disease”: Disease Symptoms and Treatment Side Effects in a Diverse Sample of Patients with Early Limited Cutaneous and Diffuse Cutaneous Systemic Sclerosis
Chelsea Perschon¹, Emilie Jaeger¹, George Greene¹, Alain Lescoat², Yen Chen³, Susan Murphy³, Sara Shaunfield¹, David Cella¹ and Dinesh Khanna³, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²University Rennes, Rennes, France, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune rheumatic disease with heterogeneous manifestations, including common symptoms such as pain, fatigue, dyspnea, and Raynaud's phenomenon. It…
Abstract Number: 2354 • ACR Convergence 2023
Is Midkine a Novel Biomarker for Acro-osteolysis in Systemic Sclerosis?
Ganiat Adeogun¹, Venkateswara Gogulamudi², Meridith Balbach¹, Anthony Donato² and Tracy Frech¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Salt Lake Veterans Affairs Medical Center, Salt Lake City, UT
Background/Purpose: Acro-osteolysis is a hand complication in systemic sclerosis (SSc) characterized by the destruction of distal digital bone possibly related to repetitive ischemia-reperfusion injury. Diagnosis…
Abstract Number: 0629 • ACR Convergence 2023
Negative Affect, Anxiety and Fatigue Moderate the Association Between Pain Intensity and Physical Function in People with Systemic Sclerosis
Daniel Whibley¹, Yen Chen¹, Anna Kratz¹, Dinesh Khanna¹ and Susan Murphy², ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Plymouth, MI
Background/Purpose: Pain is a common symptom of systemic sclerosis (SSc), affecting over 80% of those living with the condition, with over a third experiencing pain…
Abstract Number: 0790 • ACR Convergence 2023
Transcriptomic Analyses of Lung Tissues Reveals Potential Key Genes Associated with Progression of Systemic Sclerosis-Interstitial Lung Disease (SSc-ILD)
Yehya Al-Adwi¹, Johanna Westra¹, Harry van Goor¹, Leon.C.L.T van Kempen², Wim Timens¹, C.Tji Gan¹ and Douwe J Mulder¹, ¹University Medical Center Groningen, Groningen, Netherlands, ²UMCG and University of Antwerp, Groningen, Netherlands
Background/Purpose: SSc-ILD is the leading cause of death in SSc affecting around 50% of the patients. Lung tissue of patients with early-stage SSc-ILD is characterized…
Abstract Number: 1225 • ACR Convergence 2023
Nailfold Video Capillaroscopy and Its Association with Autoantibodies and Rheumatic Diseases in Pediatric Patients
Yazmin Espinosa¹, Sara Concha¹, Clara Schulze¹ and Antonia Valenzuela², ¹Pontificia Universidad Católica de Chile, Santiago de Chile, Chile, ²Pontificia Universidad Católica de Chile, Santiago, Chile
Background/Purpose: Nailfold video capillaroscopy (NVC) is useful in diagnosing secondary Raynaud's phenomenon (RP) and predicting systemic sclerosis (SSc) and other CTD in adults. Recent studies…
Abstract Number: 2357 • ACR Convergence 2023
The Involvement of CCR3-CCL24 Axis in Endothelial to Mesenchymal Transition Process and Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
Itzchak Amoyal¹, Tzipi Hornik-Lurie², Tali Zitman-Gal¹, Hilit Levy³, Ilan Vaknin³, Liat Drucker⁴, Ishai Heusler⁵, Yair Levy¹ and Shelly Tartakover Matalon¹, ¹Meir Medical Center, Autoimmune Research Laboratory, Kfar-Saba, Israel, ²Meir Medical Center, Data Research Department, Kfar-Saba, Israel, ³Chemomab Ltd, Tel Aviv, Israel, ⁴Meir Medical Center, Oncogenetics Laboratory, Kfar Saba, Israel, ⁵Meir Medical Center, Department of Obstetric and Genecology, Kfar-Saba, Israel
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular injury and extensive tissue fibrosis of the skin and internal organs. Endothelial cells (ECs),…
Abstract Number: 123 • 2023 Pediatric Rheumatology Symposium
Development of Specific Classification Criteria for Juvenile System Sclerosis Patients: A Scoping Review
Ioana Dobre¹, Suzanne Li², Natalia Vasquez Canizares³, Barbara Reich⁴, Xurong Zhao⁵, Quinn McCormick⁶ and Marinka Twilt⁵, ¹Alberta Children's Hospital/University of Calgary, Calgary, AB, Canada, ²Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, Hackensack, NJ, ³Children's Hospital at Montefiore, New York, NY, ⁴Hackensack University Medical Center, Hackensack, NJ, ⁵Alberta Children's Hospital, Calgary, AB, Canada, ⁶Hackensack Medical Hospital Network, Hackensack, NJ
Background/Purpose: Juvenile systemic sclerosis (jSSc) is associated with one of the highest morbidity and mortality rate in pediatric rheumatology, yet care recommendations are based upon…
Abstract Number: 029 • 2023 Pediatric Rheumatology Symposium
Cardiac Magnetic Resonance Imaging in Children with Systemic Lupus Erythematosus and Scleroderma Spectrum Disorders: A Single Center Experience
Meredith Rae, Tam Doan and Eyal Muscal, Baylor College of Medicine, Houston, TX
Background/Purpose: Cardiac disease is a major cause of morbidity and mortality in children with SLE and SSc. Various studies have demonstrated an association between duration…
Abstract Number: 086 • 2023 Pediatric Rheumatology Symposium
Systemic Sclerosis Overlap Syndrome: A Case Series from a Single Large Pediatric Center
Jessica Nguyen¹, Miriah Gillispie-Taylor¹, Eyal Muscal¹ and Marietta Deguzman², ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Childhood-onset systemic sclerosis (SSc) is a rare but potentially life-threatening autoimmune condition with features including immune, fibrotic, and vascular manifestations affecting the skin and…
Abstract Number: 098 • 2023 Pediatric Rheumatology Symposium
Characterization of Pulmonary Nodules in Juvenile-onset Systemic Sclerosis: A Single Center Case-Series
Jonathan Li¹, Franziska Rosser¹, Sameh Tadros¹ and Kathryn Torok², ¹UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Given the high prevalence of intestinal lung disease (ILD) in systemic sclerosis (SSc) and the low sensitivity of pulmonary function testing for diagnosing ILD,…
Abstract Number: 116 • 2023 Pediatric Rheumatology Symposium
Clinical Significance of Anti-Scl-70 Antibodies in Pediatric Lupus Patients: A Single Center Cohort
Dawn Janysek¹, Yiressy Pina², Danielle Guffey³ and Marietta De Guzman¹, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Baylor College of Medicine, Houston, TX
Background/Purpose: Production of autoantibodies is a hallmark of SLE, with ANAs as a required diagnostic feature and anti-dsDNA and anti-Smith antibodies being disease-specific. Anti-Scl-70 antibodies…
Abstract Number: 0516 • ACR Convergence 2022
Identifying Current Assessment and Treatment Strategies in Juvenile Systemic Sclerosis: An International Effort to Improve Patient Outcomes
Natalia Vasquez Canizares¹, Clare Pain², Marinka Twilt³, Amra Adrovic Yildiz⁴, Simone Appenzeller⁵, Edoardo Marrani⁶, Emanuela Del Giudice⁷, Antonella Petaccia⁸, Francesca Tirelli⁹, Gabriele Simonini¹⁰, Marco Cattalini¹¹, Ozgur Kasapcopur¹², Raju Khubchandani¹³, Kathryn Torok¹⁴, Betul Sozeri¹⁵, Biagio Castaldi¹⁶, Katherine Clarke¹⁷, Phuoc Duong¹⁷, Aybuke Gunalp¹⁸, meiping lu¹⁹, Hanna Lythgoe², Amanda Robinson¹⁴, Lauren Robinson²⁰, Paulo Rogerio Julio²¹, Susan Shenoi²², Emily Willis²³, Mustafa Çakan¹⁵, Valentina Leone²⁴, Rongjun Zheng¹⁹, Phillip Lawrence¹⁷, Franziska Rosser²⁵, Sarah Mayell², Lusine Ambartsumyan²⁶, Aurelia Minuti²⁷, Francesco Zulian²⁸ and Suzanne Li²⁹, ¹Children's Hospital at Montefiore/ Albert Einstein College of Medicine, New York, NY, ²Alder Hey Children’s NHS Foundation Trust, Liverpool, United Kingdom, ³Alberta Children's Hospital, Calgary, AB, Canada, ⁴School of Medicine, KOC University, Istanbul, Turkey, ⁵Unicamp, Campinas, São Paulo, Brazil, ⁶AOU Meyer, Florence, Italy, ⁷Sapienza University of Rome, Pediatric and Neonatology Unit, Maternal and Child Department, Rome, Italy, ⁸Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ⁹Women's and Child's Health, University Hospital of Padova, Padova, Italy, ¹⁰Meyer Children's Hospital, Florence, Italy, ¹¹Pediatric Clinic, University of Brescia, Brescia, Italy, ¹²Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Istanbul, Turkey, ¹³SRCC Children's Hospital, Mumbai, India, ¹⁴Pediatric Rheumatology, Children's Hospital of UPMC, Pittsburgh, PA, ¹⁵University of Health Sciences, Istanbul, Turkey, ¹⁶Women's and Child's Health, University Hospital of Padova, Padua, Italy, ¹⁷Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ¹⁸Istanbul University Cerrahpaşa Medical School, Istanbul, Turkey, ¹⁹Children’s Hospital of Zhejiang University Medical School, Zhejiang, China, ²⁰Hospital for Special Surgery, New York, NY, ²¹University of Campinas, Campinas, São Paulo, Brazil, ²²Seattle Children's Hospital and Research Center / University of Washington, Seattle, WA, ²³Royal Manchester Children’s Hospital, Manchester, United Kingdom, ²⁴Ismett, UPMC, Palermo, Italy, ²⁵University of Pittsburgh, Children’s Hospital of UPMC, Pittsburgh, PA, ²⁶Seattle Children's Hospital, University of Washington, Seattle, WA, ²⁷D. Samuel Gottesman Library Research and Education, Albert Einstein College of Medicine, Bronx, NY, ²⁸University of Padua, Padua, Italy, ²⁹Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, West Orange, NJ
Background/Purpose: Juvenile Systemic Sclerosis (jSSc) is an autoimmune and fibrosing disease associated with significant morbidity and mortality risk. Data on treatment is limited and based…
Abstract Number: 1069 • ACR Convergence 2022
Renal Involvement Other Than Renal Crisis in Systemic Sclerosis: A Retrospective Monocentric Cohort Study
Gaelle Becel¹, Bertrand Dunogue¹, Benjamin Chaigne¹, Benjamin Thoreau², Alexis Regent¹, Alexandre Karras³, Benjamin Terrier¹ and Luc Mouthon¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²AP-HP, Université Paris Cité, INSERM U1016, CNR UMR 8104, Paris, France, ³HEGP, Paris, France
Background/Purpose: Scleroderma renal crisis has extensively been described over the past decades because of its severity. The use of angiotensin-converting enzyme inhibitors has clearly improved…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].